For everyone concerned with the issues of pharmacovigilance and toxicovigilance

- Anniversary Symposium
- New Member Countries
- Pharmacovigilance in Sudan and Argentina
- PhD thesis in Pharmacovigilance

Twenty Year Celebrations and More!

The WHO Anniversary Symposium in Stockholm
MESSAGE FROM RALPH EDWARDS, DIRECTOR

We are very lucky to have had Ana Maria Corrêa-Nunes working with us recently. Ana Maria is from INFARMED, the Ministry of Health, Portugal, and has spent a two month sabbatical leave here in Uppsala (see photo on next page).

Ana Maria has been actively involved in developing the material gathered from the first CIOMS Communications Working Group, which met in Dublin last year. We intend to make drafts of the papers available on the Internet very soon, so that we can gather your comments and edit them further. We will then write the Good Practice Guidelines and publish these as a CIOMS monograph, probably later this year. All in all, this is really a very exciting stage in our efforts to push good communications practice high up the agenda in the field of pharmacovigilance.

In another aspect of her work with us, Ana Maria has reviewed how we process international data to generate signals. This follows our successful introduction of neural network data-mining, which we have been working on for some time. We are confident that the results will be interesting and provide more efficient ways of involving National Centres and our panel of experts in generating signals. Our aim is to reduce list-processing and to offer statistically outstanding information on new adverse drug reactions.

You'll find more information about our twenty-year celebrations on this page. I do hope we shall have the pleasure of seeing many of our international friends in Sweden in December to celebrate with us - and to take part in an extensive professional debate. Do join us!

Best wishes,

Ralph Edwards

I Ralph Edwards

20 Year Celebrations and more!

We are very pleased to announce that we are holding a WHO Anniversary Symposium in Stockholm 9-10 December, 1998.


The programme will focus on four subjects:

• Spontaneous Reporting
• Special studies in Pharmacoepidemiology
• Benefit/Risk assessments
• Communications in Pharmacovigilance.

The structure will be based on classical logic. There will be one presentation of the strengths and opportunities (thesis), one of the weaknesses and threats (anti-thesis) followed by a concluding session (synthesis).

The anniversary symposium, which is reserved for scientific debate, will be followed by a one-day conference on 11 December at which representatives of regulatory authorities will present their perspectives on the four selected subjects.

As well as generating important professional debate, this symposium is an excellent chance to celebrate no less than three anniversaries:

• 50th Anniversary of the WHO
• 30th Anniversary of the WHO Drug Monitoring Programme
• 20th Anniversary of the WHO Collaborating Centre - the UMC, Uppsala

We look forward to welcoming colleagues from around the world to this special event.

We have commissioned IIR Ltd to take care of all practical arrangements for the symposium. Invitations will be distributed in the near future by IIR. If you want to make sure you get an invitation, please contact:

Anouk Cruttenden, IIR Ltd
Tel: +44-171-9155076
Fax: +44-171-8505001
E-mail: acruttenden@iir-conferences.com
or Sten Olsson at the Uppsala Monitoring Centre.
NEW TEAM MEMBER MAKES IT 18!

Malin Stähl has joined the Uppsala team, bringing the group to 18 members. Malin Stähl is a Biomedical Scientist and is working on Signal Development and other projects.

Our most recent group photo shows almost the full team. It was taken during our Strategic Planning Week in May at Haga Slott, a beautiful old Swedish castle. It is always difficult to get us all in the one place at any one time, but on this occasion we managed to get 17 out of 18, which wasn’t bad! (Only Monica Pettersson is missing - absent on maternity leave).

Ana Maria Corrêa-Nunes INFarmED, the Ministry of Health, Portugal. Working temporarily at the UMC.

SIGNS DEVELOPMENT PROJECT

A working group at the UMC has begun reviewing signal detection and evaluation. One of the goals of the Centre is to maximize the usefulness of the WHO database in detecting signals, and we are constantly evaluating new ways of doing this. We have previously mentioned our new methodology for detection of drug adverse reaction associations, which uses a data-mining technique based on Bayesian statistics (see Recent Publications for further details). We are also collaborating with IMS, who hold drug usage and prescription data. So it seemed appropriate to look at the signal process with these in mind.

From our own discussions we have a vision of what we can provide to you, our worldwide colleagues. But to ensure that we really deliver the service you require, we need as much feedback as possible. We hope this project will enable us to provide several new products, which will also be available to industry colleagues and will help to fund the rest of our new improved signal analysis and detection procedure.

We will provide more details at the WHO National Centres annual meeting in Tokyo in September. Afterwards, we will distribute a questionnaire to all National Centres and industry, through which we will be able to collect the information we need to refine the proposed signal process based on your views.

NEW INTERIM BOARD APPOINTED FOR THE UMC

A new interim Board to oversee the affairs of the UMC was recently appointed. The Chairman is Alf Nilsson. This follows Swedish Government queries about technical accounting issues at the Centre (the Swedish Government provides core funding for the Centre). There is no question about the financial probity of the accounts or of the misuse of funds, and we hope these queries will be resolved quickly.

WHO DICTIONARIES

This year’s first WHO Dictionaries Users’ Group meeting was held at the Annual DIA meeting in Boston on 8 June.

Marie Lindquist, Ralph Edwards, Mats Persson and Anna Lindquist attended from the Uppsala Monitoring Centre.

Our new projects: Neural Network Data-Mining; Analysis with drug utilization data from IMS, ICD-WHOART amalgamation; The New WHO Drug Dictionary, DD changes/frozen databases and the New Adverse Reactions Database - were presented by Marie Lindquist.

Further information and minutes from the meeting can be found at our website homepage (http://www.who-umc.org).

The next Users’ Group meeting will be held at the DIA Clinical Data Management meeting in Berlin, Germany, 26 October, 1998.

CURRENT EDITIONS OF THE WHO DICTIONARIES

The current computerized editions of the Drug Dictionary, DD Access (Standard version) and Adverse Reaction Terminology contain information up to and including the second quarter of 1998.

The new paper-print edition of the Drug Dictionary, (dated 31 March, 1998) containing the new ATC-codes, is currently available from the UMC.

New updated versions of the paper-print English, German, French and Portuguese Adverse Reaction Terminologies are also currently available.
COURSES & MEETINGS
in PHARMACOVIGILANCE

COURSES

- The National ADR Monitoring Centre in Malaysia is organizing a national conference with invited guests from the ASEAN region, taking place on 12-13 October, 1998. For more information please contact:
  Ms Abida Haq
  Tel: +60-3-7573611
  Fax: +60-3-7562924
  E-mail: ah@bpfk.gov.my

- Pharmacovigilance Training Course in the Eastern Mediterranean Region on 16-18 October, 1998. (This course will probably be held in Rabat, Morocco).
  For more information please contact:
  Dr A. Alwan, Director, Health Services Department, WHO, EMRO
  Tel: +20-3-483 0090/96/97/99
  Fax: +20-3-483 8916

- An International Workshop on Adverse Drug Reaction Monitoring will be held at J.N. Medical College, Aligarh, India on 9-12 November, 1998.
  For more information please contact:
  Professor K.C. Singhal
  Tel: +91-571-400584
  Fax: +91-571-508013

- A course on Adverse Drug Reactions is being organized by Healthcare Education Services Ltd, Edinburgh, UK on 1-2 December, 1998.
  For more information please contact:
  Health Education Services Ltd
  Tel: +44-131-557 2477
  Fax: +44-131-557 6778

- International Training Course in Adverse Reactions and ADR monitoring at the Uppsala Monitoring Centre, Uppsala, Sweden. We have decided to postpone this two week training course until May, 1999. Invitations will however be distributed well in advance.
  For more information please contact:
  Sten Olsson at the UMC

MEETINGS

- The DIA is holding a workshop on Monitoring Drug Safety - A Shared Responsibility at the State Institute for Drug Control in Prague, Czech Republic on 7-8 September, 1998. For more information please contact:
  The Drug Information Association, USA
  Tel: +1-215-628 2288, Fax: +1-215-641 1229
  E-mail: dia@diahome.org

- IIR Ltd, is organizing a conference on, Optimizing & Improving Pharmacovigilance & Benefit/Risk Assessment at One Great George St, London, UK on 15-16 September, 1998. A pre-conference briefing on, Developing Strategies for Successful Signal Generation will be held on 14 September and a post-conference workshop on Examining Causality Assessment on 17 September.
  For more information please contact:
  Anouk Cruttenden, IIR Ltd
  Tel: + 44-171-915 5076, Fax: + 44-171-850 5001
  E-mail: acruttenden@iir-conferences.com

- The DIA is holding a seminar on, Medical Approach in Diagnosis and Management of ADRs at the Hotel Sofitel Paris Forum Rive Gauche, Paris, France on 24-25 September, 1998.
  For more information please contact:
  The Drug Information Association - European Office
  Tel: +41-61-386 9393, Fax: +41-61-386 9390
  E-mail: diaeuropa@stepnet.de

- The European Society of Pharmacovigilance (ESOP) is organizing its sixth annual meeting at the Hotel Bara, Budapest, Hungary on 28-29 September, 1998.
  For more information please contact:
  János Borvendég or Sándor Elek,
  The National ADR Monitoring Centre
  Tel/Fax: +36-1-215 8977

- Nordic Vaccine Meeting 1998 - Focus on Surveillance and Vaccine Research at the Congress Hotel Majvik, Kirkkonummi, Finland on 7-8 October, 1998.
  For more information please contact:
  Kari Lankinen (Chairman, organizing committee)
  Tel: +358-9-4744 8667, E-mail: kari.lankinen@ktl.fi
  Nordic Vaccine Meeting, Secretariat
  Fax: +358-9-4744 8675

- IBC is organizing a conference entitled: Clarifying Current International Regulatory Reporting Requirements for Adverse Drug Reactions at One Whitehall Place, London, UK on 27-28 October, 1998. A pre-conference workshop on: Selecting, Implementing and Managing Information Systems to Effectively Meet Reporting Requirements for ADRs will be held on 26 October at Café Royal, London, UK.
  For more information please contact:
  Laura Viberti at IBC
  Tel: +44-171-453 5496, Fax: +44-171-636 6858
  E-mail: cust.ser@ibcuk.co.uk
FORTHCOMING PUBLICATIONS

In September this year we plan to publish the report on the International Conference on Effective Communications in Pharmacovigilance, held last September in Erice, Sicily. This is currently being printed in Kumasi, Ghana and you will be able to obtain a copy from the Uppsala Monitoring Centre. Participants in the conference will receive their own copies automatically.

The second edition of National Pharmacovigilance Systems is also due to be published in September. Following detailed updating of the Country Profiles data, the second edition will contain a very comprehensive collection of individual country information. It will have profiles from 57 countries, with 12 new countries and 2 new vaccine centres. For more information contact Sten Olsson at the Uppsala Monitoring Centre.

PhD thesis on Pharmacovigilance. Dr Ronald Meyboom, the Netherlands.

Ronnie Meyboom has prepared a PhD thesis on signal detection in pharmacovigilance. The aim of this work is to improve our understanding of the scientific processes underlying the early warning function of spontaneous reporting, and to help improve efficiency and reliability in pharmacovigilance.

The thesis begins with a retrospective analysis of a large number of subsequent drug-related problems encountered by the (former) Dutch pharmacovigilance centre. Study targets were the characteristics of the drugs, the problems involved and the composition of the data constituting signals. A general review follows on what signals are, where they can be found, why something is likely to be a signal and why not, and signal management.

The thesis looks in detail at the role of standardized case causality assessment. In the final chapter the various findings and views are put into perspective and an attempt is made to glimpse future developments and changes in pharmacovigilance and the study of approved medicines. The thesis contains a lot of information of potential value in improving pharmacovigilance globally.

The supervisors are clinical pharmacologist, Professor Frank Gribnau, and clinical pharmacist, Dr Chiel Hekster, of the Nijmegen University Hospital. Professor Ralph Edwards has been invited to contest the thesis which will be defended on Tuesday 13 October at the Nijmegen University.

The thesis will be published in book form by the Netherlands Pharmacovigilance Foundation (LAREB) and is currently available. It will be distributed by LAREB to all national centres. You can obtain additional copies from LAREB:

Goudsbloemvallei 7,
5237 MH Den Bosch,
The Netherlands
Tel: +31 (0)73 646 9700
Fax: +31 (0)73 642 6136
E-mail: info@lareb.nl

RECENT PUBLICATIONS

Dictionnaire de Pharmacovigilance Médicale

This is the second edition of a dictionary, compiled by Dr Pierre Biron, Department of Pharmacology, University of Montréal, Canada, It has explanations of all the most common words and concepts used in pharmacovigilance and pharmacoepidemiology. It is a 215 page document written in French, with all technical terms translated into English.

Send your order to:
La Librairie de l'Université de Montréal
Suite L-315, Main Building, POB 6128, Downtown Station, Montréal, Québec, Canada H3C 3J7.
Tel: +1 514-343 6210 Fax: +1 514-343 6350
Cost: 14.70 CAN$ plus postage. Major credit cards are accepted.

From the UMC

The Uppsala Monitoring Centre


Other factors of potential relevance in Sudan are:
- Genetically or environmentally determined adverse reactions (e.g. G6PD deficiency)
- Problems relating to traditional remedies, such as adverse effects, interactions (e.g. karakadee, aradeb) and inefficacy
- Non-compliance (wrong indication, dose, duration or route)
- Availability and affordability of essential drugs
- Rational budgetary spending
- Misleading promotion in the community
- Adverse effects of repellants against disease spreading vectors (e.g. gammexane)
- Transport and storage of drugs under harsh conditions.

Proposals
Pharmacovigilance in Sudan could be started as a regional activity in an environment where it is most likely to succeed, such as the university hospital in Khartoum. Similar activities can then be introduced at other interested hospitals throughout the country, in collaboration with the established centre and using the same methodology. It needs to be made clear from the beginning that pharmacovigilance is a national (i.e. federal) activity, for and by all healthcare practitioners and institutes throughout the country.

Pharmacovigilance could be developed in combination with poison control as well as drug information and pharmaceutical care.

Pharmacovigilance is also more likely to succeed if there is simultaneous investment in therapeutics education. A concrete design for a training program for pharmaceutical and medical professionals has been provided to EMRO.

Given the many competent and dedicated people working at the Directorate of Pharmacy, the universities and elsewhere in the healthcare system, we can expect that pharmacovigilance will thrive and develop into a useful tool for improving the rational and safe use of medical drugs in Sudan.

REPORT ON THE PHARMACOVIGILANCE PROGRAMME FOR THE NORTHEAST OF ARGENTINA

Dr Mabel Valsecia, Chief of Regional Centre of Pharmacovigilance, Associate Professor of Pharmacology, National Northeast University - School of Medicine, Corrientes, Argentina.

Mabel Valsecia has been involved in research covering the first three years of implementation of the Pharmacovigilance Programme of the Department of Pharmacology, the National Northeast University School of Medicine, Corrientes, Argentina. This is a node of the
National System of Pharmacovigilance of the National Administration of Drugs Food and Medical Technology (ANMAT).

Pharmacovigilance studies in Argentina are few and limited. Before this study there had been no studies at all in the northeast region.

**Drug-Induced Pathologies**
The study was based on 900 voluntary ADR reports received from five states in the northeast of Argentina. Reports were also received from Asuncion, capital of Paraguay. Reporting revealed a significant incidence of severe drug-induced pathologies. Etiological investigations were carried out to test drug-related and/or non-drug causes, in order to provide therapeutic advice regarding the incriminated drugs.

The study used the reports from the National System of Pharmacovigilance for spontaneous reporting. Several hospitals and health centres throughout the northeast region sent in ADR reports. Physicians and other healthcare personnel then received relevant information from the reporting centre to assist them in treating patients with drug-induced diseases.

Feedback information from the reports is published as pharmacovigilance bulletins in postgraduate course journals. All individual reports are analyzed, coded and then sent on to the National Pharmacovigilance Centre. The relevant information is then forwarded to the Uppsala Monitoring Centre, Sweden.

**Outcomes**
The study showed that 83% of the reports came from physicians, 12% from medical students, 3% from physiotherapists and the rest from pharmacists, dentists, nurses and consumers.

75% of the ADRs were of type A: predictable and dose-related, mainly an extension of the pharmacological effects, drug interactions, side effects and direct toxicity. The rest were of type B: unexpected and unpreventable, such as anaphylactic reactions, allergic vasculitis or hepatitis. 30% of the ADRs were classified as being due to irrational prescribing with half of them attributed to medical negligence. The adverse reaction was classified as mild in 16%, moderate in 50% and serious in 14% of cases (12 fatal). 16% of these required pharmacological treatment and 5% resulted in hospitalization.

**New Signals**
The ADR reporting programme identified previously unrecognized signals (e.g. night terror associated with Oxybutynin). ANMAT obtained this information about Oxybutynin and passed it on to the Uppsala Monitoring Centre.

Some of the major conclusions drawn from the study are:
- The detection of a significant incidence of severe drug-induced pathologies
- Confirmation of the need for therapeutic drug monitoring and the extension of pharmacovigilance related studies
- The need for educational intervention, both at undergraduate and postgraduate level, to improve the rational use of drugs.

More than anything the study shows that the Pharmacovigilance Programme needs to expand in Argentina and in Latin America.

**EUROPEAN UNION PRINCIPLES FOR PROVIDING THE WHO WITH PHARMACOVIGILANCE INFORMATION**

In January 1998 the Committee for Proprietary Medicinal Products (CPMP), Pharmacovigilance Working Party discussed and agreed Principles for providing the WHO headquarters in Geneva and the WHO Collaborating Centre for International Drug Monitoring in Uppsala with pharmacovigilance information.

The Principles were agreed under the following headings:
- Adverse Drug Reaction Reports
- Rapid Alerts
- Infofaxes
- Other Pharmacovigilance Information for Centrally Authorized Products
- Outcomes of Referrals
- CPMP Position Statements on Pharmacovigilance Issues

In addition, Member States will provide further information for nationally authorized products according to their legislation and agreements.

The Principles, available in document CPMP/PhVWP/053/98, may be obtained from the Uppsala Monitoring Centre.

---

**NATIONAL CENTRES ANNUAL MEETING**

The 21st Annual Meeting of National Centres Participating in the WHO Programme for International Drug Monitoring will be organized in Tokyo, by the Ministry of Health & Welfare, Japan, on 7-10 September, 1998.

**For more information contact:** Dr Martijn ten Ham, WHO, Geneva:

Tel: +41-22-7913638  Fax: +41-22-7914730  E-mail: tenhamm@who.ch
ESTONIA, IRAN and ZIMBABWE have now started to submit ADR reports to the Uppsala Monitoring Centre and have thus fulfilled all criteria for becoming full members of the WHO Programme, which now has 53 members. MEXICO and VIETNAM have recently applied for membership of the programme. During the last year 6 countries have joined the programme and an additional 4 have applied for membership.

Communications details for the new national centres:

**ESTONIA**
Dr Maia Uusküla
State Agency of Medicines
Kalevi 4, P.O.Box 150
EE-2400 Tartu
Tel: +372-7-441219
Fax: +372-7-441549
E-mail: maia@sam.ee

**IRAN**
Dr Mohammed Sharifzadeh
Iranian Drug Information Centre
Under-Secretary for Curative and Drug Affairs, Building No 3
Fakhr-e Raz, Enghlab Ave
Tehran 13145
Tel: +98-21-6405569/6419306
Fax: +98-21-675868

**ZIMBABWE**
Ms Gugu Mahlangu
Drugs Control Council
P.O.Box UA 599, 106 Baines
Union Ave
Harare
Tel: +263-4-792165
Fax: +263-4-736980
E-mail: mcaz@AfricaOnline.Co.Zw

**MEXICO**
Dra Carmen Becerril Martinez
Gauss No 4, Piso 7, Col Casa Blanca
C.P. 11590Mexico City
Tel: +52-2034378
Fax: +52-2034378
E-mail: cpteum@mpsnet.com.mx

**VIETNAM**
Prof Hoang Tich Huỳêñ
Adverse Drug Reaction Centre
Institute for Drug Quality Control
Ministry of Health, 48 Hai Ba Trung Street, Hanoi
Tel: +84-4-245292
Fax: +84-4-8231253

**BRAZIL**
In February 1998, the Instituto da Crinça, Sao Paulo, headed by Dr Anthony Wong, was designated as a Reference Centre for the Development and Promotion of Pharmacovigilance, within the WHO Program for International Drug Monitoring. The Institute is actively involved in establishing and promoting pharmacovigilance in Brazil.

---

**the Uppsala Team**

Director: Professor Ralph Edwards
Manager (External Affairs): Sten Olsson
Manager (Internal Affairs): Cecilia Binell
Manager (Marketing): Liza Storm
Manager (Research & Development): Marie Lindquist
Sales & Promotions Manager: Mats Persson
Scientists:
Mohamed H. Farah (Traditional Medicines)
Jonathan Edwards (Information Systems)
Malin Ståhl (Biomedical)
Andrew Bate (Neural Network Methodology)

Pharmacists:
Helena Fucik
Monica Pettersson
Malin Zaar
Erika Walette
Anna-Karin Flygare
Anna Lindquist
Maria Bergström
Inger Forsell

External Affairs Assistant: Professor Ralph Edwards
Internal Affairs Assistant: Sten Olsson
Sales Assistant: Cecilia Binell

---

**Communications information**

Uppsala Reports © the Uppsala Monitoring Centre 1998
Postal Address: the Uppsala Monitoring Centre, Stora Torget 3 S-753 20 Uppsala, Sweden
Telephone: +46 (18) 65 60 60  Fax: +46 (18) 65 60 80  e-mail: who.drugs@who.pharmasoft.se - Personal e-mail messages may be sent to any members of the team by putting their name (e.g. ralph.edwards or anna.lindquist) in place of, who.drugs
Internet: http://www.who.umn.org